SCOLR drops PE plans
This article was originally published in The Tan Sheet
Executive Summary
SCOLR Pharma announces Feb. 6 it will no longer continue the development of a 12-hour CDT-based phenylephrine formulation. The Bellevue, Wash.-based firm says the recently completed non-optimized CDT-based extended release PE trial "provided valuable data but does not justify continued internal development." SCOLR Pharma's VP and Chief Technology Officer Stephen Turner says the firm plans to focus its resources on an extended release formulation of pseudoephedrine with the goal of filing an ANDA later this year...